Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunogenicity and Safety of Two RSV Vaccine Strategies in Lung and Allogeneic HSCT Recipients
NCT07863401Phase 2Not yet recruiting
- Sponsor
- Hospices Civils de Lyon
- Start
- Oct 2026
- Primary completion
- Jun 2028
- Countries
- 1
01
Overview
Phase 2 trial of respiratory syncytial virus vaccine (recombinant, adjuvanted) and RSVpreF vaccine in respiratory syncytial virus infection (RSV) (2 arms), sponsored by Hospices Civils de Lyon. Primary endpoint: RSVpreF-binding antibody response. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
respiratory syncytial virus vaccine (recombinant, adjuvanted)RSVpreF vaccine
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT07863401.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07863401.